Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 10/20 | 0.72 |
| ▸ | KMT2A | Q03164 | 10/20 | 0.72 |
| ▸ | MAPT | P10636 | 9/20 | 0.72 |
| ▸ | LMNA | P02545 | 6/20 | 0.72 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.72 |
| ▸ | NPC1 | O15118 | 3/20 | 0.72 |
| ▸ | RAB9A | P51151 | 3/20 | 0.72 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.72 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.72 |
| ▸ | RELA | Q04206 | 1/20 | 0.72 |
| ▸ | GAA | P10253 | 2/20 | 0.63 |
| ▸ | HPGD | P15428 | 2/20 | 0.57 |
| ▸ | ALOX12 | P18054 | 3/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.50 |
| ▸ | POLB | P06746 | 3/20 | 0.50 |
| ▸ | BLM | P54132 | 2/20 | 0.50 |
| ▸ | ALPL | P05186 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1132163 | 1.00 | MEN1 (0.72) | MEN1KMT2AMAPTLMNASMN1; SMN2 | |
| SCHEMBL11353829 | 0.83 | MAPT (0.61) | MEN1KMT2AMAPTLMNASMN1; SMN2 | |
| SCHEMBL26135296 | 0.79 | GAA (0.65) | MEN1KMT2AMAPTLMNASMN1; SMN2 | |
| SCHEMBL26135639 | 0.79 | GAA (0.65) | MEN1KMT2AMAPTLMNASMN1; SMN2 | |
| SCHEMBL26135297 | 0.79 | GAA (0.65) | MEN1KMT2AMAPTLMNASMN1; SMN2 | |
| SCHEMBL11282738 | 0.79 | MEN1 (0.58) | MEN1KMT2AMAPTLMNASMN1; SMN2 | |
| SCHEMBL28045552 | 0.79 | MEN1 (0.58) | MEN1KMT2AMAPTLMNASMN1; SMN2 | |
| SCHEMBL1132529 | 0.79 | MAPT (0.60) | MEN1KMT2AMAPTLMNASMN1; SMN2 | |
| SCHEMBL1132528 | 0.79 | MAPT (0.60) | MEN1KMT2AMAPTLMNASMN1; SMN2 | |
| SCHEMBL8494526 | 0.79 | MAPT (0.57) | MEN1KMT2AMAPTLMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9512066-B2 | Enhancers of protein degradation | MAX-DELBRUCK-CENTRUM FUR MOLEKULARE MEDIZIN (DE) | 2016-12-06 | — | — | US | claimed |
| US-20120282629-A1 | Enhancers of Protein Degradation | MAX-DELBRUCK-CENTRUM FUR MOLEKULARE MEDIZIN (DE) | 2012-11-08 | — | — | US | claimed |
| EP-2488485-A1 | ENHANCERS OF PROTEIN DEGRADATION | Max-Delbrück-Centrum für Molekulare Medizin (DE) | 2012-08-22 | — | — | EP | claimed |
| WO-2011020883-A9 | ENHANCERS OF PROTEIN DEGRADATION | Max-Delbrück-Centrum für Molekulare Medizin (DE) | 2012-07-12 | — | — | WO | claimed |
| WO-2011020883-A1 | ENHANCERS OF PROTEIN DEGRADATION | Max-Delbrück-Centrum für Molekulare Medizin (DE) | 2011-02-24 | — | — | WO | claimed |
| EP-2287149-A1 | Enhancers of protein degradation | MAX-DELBRÜCK-CENTRUM FÜR MOLEKULARE MEDIZIN (DE) | 2011-02-23 | — | — | EP | claimed |
| US-9512066-B2 | Enhancers of protein degradation | MAX-DELBRUCK-CENTRUM FUR MOLEKULARE MEDIZIN (DE) | 2016-12-06 | — | — | US | disclosed |
| US-20120282629-A1 | Enhancers of Protein Degradation | MAX-DELBRUCK-CENTRUM FUR MOLEKULARE MEDIZIN (DE) | 2012-11-08 | — | — | US | disclosed |
| EP-2488485-A1 | ENHANCERS OF PROTEIN DEGRADATION | Max-Delbrück-Centrum für Molekulare Medizin (DE) | 2012-08-22 | — | — | EP | disclosed |
| WO-2011020883-A9 | ENHANCERS OF PROTEIN DEGRADATION | Max-Delbrück-Centrum für Molekulare Medizin (DE) | 2012-07-12 | — | — | WO | disclosed |
| WO-2011020883-A1 | ENHANCERS OF PROTEIN DEGRADATION | Max-Delbrück-Centrum für Molekulare Medizin (DE) | 2011-02-24 | — | — | WO | disclosed |
| EP-2287149-A1 | Enhancers of protein degradation | MAX-DELBRÜCK-CENTRUM FÜR MOLEKULARE MEDIZIN (DE) | 2011-02-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120282629-A1 | Enhancers of Protein Degradation | HTT, HYPK, TFEB | MEN1 3413/4885KMT2A 2000/4885MAPT 149/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.